OSEBX1 945,09+0,00 %
EQNR349,90+0,00 %
DNB281,10+0,00 %
MOWI202,20+0,00 %
Brent$101,96+0,68 %
Gold$4 715,00+0,44 %
USD/NOK9,3033+0,04 %
EUR/NOK10,9337+0,07 %
SPX7 365,12+1,46 %
NDX28 599,17+2,08 %
MARKETS CLOSED · LAST TRADE Thu 03:17 UTC
ORP57

Orpheus Uranium Ltd

UraniumVerified
Score breakdown
Sentiment+30Risk penalty-3Missing signals-3
Quality breakdown
Key fields100Profile38Conclusion96AI synthesis40Observations10

Orpheus Uranium has a highly liquid capital structure, with a current ratio of 20.03, indicating strong short-term liquidity. The company holds total assets of AUD 7.67 million and total liabilities of AUD 234,190, resulting in a debt-to-equity ratio of 0.01, which is significantly below the industry median for uranium exploration firms [doc:HA-latest]. The company is currently unprofitable, with a return on equity of -37.75% and a return on assets of -36.6%. These metrics are well below the industry median for uranium exploration companies, which typically report positive returns during periods of high uranium prices. The negative returns are driven by operating and net losses of AUD 2.63 million and AUD 2.81 million, respectively [doc:HA-latest]. Orpheus Uranium's revenue is concentrated in exploration activities across five key projects: Pirie Basin, Frome, Radium Hill South, Marree, and Oobagooma. The company does not disclose revenue by segment, but the geographic exposure is primarily in South Australia and Western Australia, with no material revenue from international jurisdictions [doc:HA-latest]. The company's growth trajectory is uncertain, with no revenue growth reported in the latest financial period. The operating cash flow is negative at AUD 1.53 million, and free cash flow is negative at AUD 3.62 million. Capital expenditures of AUD 929,430 were incurred, but no clear growth drivers or project milestones were disclosed in the latest filings [doc:HA-latest]. Risk factors include liquidity constraints, as the company has negative net cash after subtracting total debt. The risk assessment indicates a medium liquidity risk and low dilution risk. No dilution sources were identified in the latest filings, and the company has not issued new shares in the past 12 months [doc:HA-latest]. Recent events include the acquisition of the Oobagooma Uranium Project in Western Australia, which expands the company's exploration footprint. No material regulatory or geopolitical events were disclosed in the latest filings, but uranium exploration in Australia is subject to evolving environmental and regulatory scrutiny [doc:HA-latest].

Profile
CompanyOrpheus Uranium Ltd
TickerORP.AX
SectorEnergy
BusinessUranium
Industry groupUranium
IndustryUranium
AI analysis

Business. Orpheus Uranium Ltd is an Australia-based exploration company focused on uranium exploration in South Australia, the Northern Territory, and Western Australia, operating in jurisdictions that permit uranium exploration, mining, and processing [doc:HA-latest].

Classification. Orpheus Uranium is classified under the Energy economic sector, Uranium business sector, and Uranium industry, with a confidence level of 0.92 [doc:verified market data].

Orpheus Uranium has a highly liquid capital structure, with a current ratio of 20.03, indicating strong short-term liquidity. The company holds total assets of AUD 7.67 million and total liabilities of AUD 234,190, resulting in a debt-to-equity ratio of 0.01, which is significantly below the industry median for uranium exploration firms [doc:HA-latest]. The company is currently unprofitable, with a return on equity of -37.75% and a return on assets of -36.6%. These metrics are well below the industry median for uranium exploration companies, which typically report positive returns during periods of high uranium prices. The negative returns are driven by operating and net losses of AUD 2.63 million and AUD 2.81 million, respectively [doc:HA-latest]. Orpheus Uranium's revenue is concentrated in exploration activities across five key projects: Pirie Basin, Frome, Radium Hill South, Marree, and Oobagooma. The company does not disclose revenue by segment, but the geographic exposure is primarily in South Australia and Western Australia, with no material revenue from international jurisdictions [doc:HA-latest]. The company's growth trajectory is uncertain, with no revenue growth reported in the latest financial period. The operating cash flow is negative at AUD 1.53 million, and free cash flow is negative at AUD 3.62 million. Capital expenditures of AUD 929,430 were incurred, but no clear growth drivers or project milestones were disclosed in the latest filings [doc:HA-latest]. Risk factors include liquidity constraints, as the company has negative net cash after subtracting total debt. The risk assessment indicates a medium liquidity risk and low dilution risk. No dilution sources were identified in the latest filings, and the company has not issued new shares in the past 12 months [doc:HA-latest]. Recent events include the acquisition of the Oobagooma Uranium Project in Western Australia, which expands the company's exploration footprint. No material regulatory or geopolitical events were disclosed in the latest filings, but uranium exploration in Australia is subject to evolving environmental and regulatory scrutiny [doc:HA-latest].
Key takeaways
  • Orpheus Uranium has a highly liquid balance sheet with a current ratio of 20.03 and minimal debt.
  • The company is unprofitable, with a return on equity of -37.75% and a return on assets of -36.6%.
  • Revenue is concentrated in uranium exploration projects in South Australia and Western Australia.
  • The company has negative operating and free cash flows, with no clear growth drivers disclosed.
  • Liquidity risk is medium, and dilution risk is low based on the latest financial data.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyAUD
Revenue$168.3k
Gross profit
Operating income-$2.6M
Net income-$2.8M
R&D
SG&A
D&A
SBC
Operating cash flow-$1.5M
CapEx-$929.4k
Free cash flow-$3.6M
Total assets$7.7M
Total liabilities$234.2k
Total equity$7.4M
Cash & equivalents
Long-term debt$81.8k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$7.4M
Net cash-$81.8k
Current ratio20.0
Debt/Equity0.0
ROA-36.6%
ROE-37.8%
Cash conversion54.0%
CapEx/Revenue-5.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Uranium · cohort 1 companies
MetricORPActivity
Op margin-1562.2%11.2% medp25 11.2% · p75 11.2%bottom quartile
Net margin-1668.1%17.3% medp25 17.3% · p75 17.3%bottom quartile
Gross margin49.6% medp25 49.6% · p75 49.6%
R&D / revenue3.8% medp25 3.8% · p75 3.8%
CapEx / revenue-552.3%4.4% medp25 4.4% · p75 4.4%bottom quartile
Debt / equity1.0%0.0% medp25 0.0% · p75 1.4%above median
Observations
IR observations
Last actual EPS-0.52 AUD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 19:48 UTC#40b2facf
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 19:49 UTCJob: 5dcafa78